hims & hers

San Francisco

732 Total Employees

Year Founded: 2017

View Website

hims & hers Company Growth, Stability & Outlook

Updated on September 08, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about hims & hers and has not been reviewed or approved by hims & hers.

What's the stability & growth outlook for hims & hers?

Strengths in scale, revenue momentum, and international expansion are accompanied by margin compression, negative cash flow in Q2 2026, and sensitivity to GLP‑1 supply and regulatory dynamics. Together, these dynamics suggest solid commercial leadership and continued growth potential that will depend on stabilizing profitability and cash generation amid competitive and therapy‑mix pressures.

Key Insight for Candidates

Defining tradeoff: category-leading growth is tightly coupled to therapy mix—especially GLP-1s—driving sharp margin and results swings. When supply or regulation forces shifts (e.g., compounded to branded), teams rapidly reprice, rebalance marketing, and retool ops. Expect fast scaling with abrupt pivots and relentless focus on unit economics.

Evidence in Action

Guidance-Driven Operating Cadence — 2026 revenue guidance of $3.1–$3.3B and Q3 guidance of $880–$900M anchor quarterly planning and prioritization. Employees sequence launches, hiring, and spend to hit guidance checkpoints, creating predictability while accelerating projects that directly move revenue and subscriber growth.
GLP‑1 Mix Discipline — The 2026 GLP‑1 transition from compounded to branded obesity drugs, including Wegovy and Zepbound, formalizes rapid therapy‑mix rebalancing. Teams expect swift strategy shifts, supplier pivots, and messaging updates to protect margins and continuity when drug availability, partnerships, or costs change.

Positive Themes About hims & hers

Strong Revenue Growth: Revenue rose 59% in 2025 to about $2.35B and accelerated to 38% year over year in Q2 2026 (~$753M), with management guiding to $3.1–$3.3B for full‑year 2026 and continued multi‑hundred‑million quarterly revenue in 2026.
Strong Market Position & Advantage: The company is described as materially larger than private DTC peers, with materials citing third‑party data that it was roughly twice the size of the next largest U.S. telehealth provider in 2025 and independent overviews placing it within a small cohort of top players.
Market Expansion: International revenue surged to roughly $131M in Q2 2026 from about $8M a year earlier (a >16x increase) aided by the Eucalyptus acquisition, expanding presence across Australia, the U.K., Germany, Canada, and Japan.

Considerations About hims & hers

Declining Profitability: After approximately $128M of net income in 2025, 2026 results included net losses (e.g., Q1: –$92M; Q2: –$86M) and gross margin fell to ~64–65% as the mix shifted toward branded GLP‑1s and international operations.
Cash Flow Strain: Q2 2026 operating cash flow turned negative (about –$36M) and free cash flow was around –$68M, reflecting working‑capital needs and investment during the scale‑up.
Short-Term or Unsustainable Growth: Growth was uneven (slow in Q1 2026, re‑accelerating in Q2) and is sensitive to therapy mix, manufacturer partnerships, and GLP‑1 supply and regulatory dynamics, as seen in the costly pivot from compounded to branded obesity drugs.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

These insights are generated using AI and may not reflect internal data or verified company information. They are intended solely for general informational purposes and should not be considered a definitive assessment of the company’s reputation. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.